Baropharm wrapped up the first day of its IPO subscription for general investors on the 2nd. With the offering price fixed at the bottom of the hoped-for price range during institutional investor demand forecasting, attention is focused on what results the public subscription will bring. Mirae Asset Securities is the lead underwriter of Baropharm's offering.

■ First-Day Subscription Results As of the first day of subscription on the 2nd, the total number of subscriptions was tallied at 12,020. The expected number of shares for equal allocation is 18.51 shares, and the proportional allocation competition ratio recorded 3.60 to 1.

■ Offering Price Fixed at Bottom of Range Baropharm's confirmed offering price is 16,400 won. The initial hoped-for price range was between 16,400 won and 20,200 won, and the offering price was set at the lowest end. In the earlier demand forecasting for institutional investors conducted from the 22nd to the 28th of last month, the competition ratio was recorded at 152.36 to 1.

Baropharm, founded in 2019, operates an integrated pharmacy platform. The company conducts its business based on an integrated pharmaceutical ordering solution that connects pharmacies with pharmaceutical wholesalers.

■ Upcoming Schedule and Listing Date Attention is focused on what subscription trends will emerge on the 3rd, the final day of subscription. After completing the general subscription on the 3rd, Baropharm plans to carry out the allocation announcement on the 5th, along with the refund of subscription deposits and payment procedures. The scheduled KOSDAQ listing date is the 11th.

[※ This article is for reference in making investment decisions, and the final responsibility for investments lies with the investor.]